ASU, Pfizer Partner on $5M Type 2 Diabetes Biomarker Project | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Arizona State University's Biodesign Institute will lead a study with partners at Pfizer, the Phoenix VA Healthcare System, and the University of Arizona's BIO5 Institute aimed at discovering protein biomarkers to predict cardiovascular disease in people with type 2 diabetes.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.